Sitagliptin: clinical trials recruiting now

FDA drug label

FDA-approved

Yes. Sitagliptin appears in the FDA drug-label database. Marketed as Sitagliptin.

Drug class

Dipeptidyl Peptidase 4 Inhibitor (FDA established pharmacologic class)

Mechanism of action

Dipeptidyl Peptidase 4 Inhibitors (as stated on the FDA label)

FDA-approved use

Sitagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Sitagliptin Tablets is not recommended in patients with type 1 diabetes mellitus. Sitagliptin Tablets have not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Sitagliptin Tablets. [see Warnings and Precautions (5.1) ]. Sitagliptin Tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Sitagliptin Tablets are not recommended in patients with type 1 diabetes mellitus. ( 1 ) Sitagliptin Tablets has not been studied in patients with a history of pancreatitis. ( 1 )

FDA recalls / enforcement

FDA label via openFDA